Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory …
Full AWH analysis →
Competitive advantage assessment
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Aspira Women's Health Inc. ranks #59 of 62
scored companies in Diagnostics & Research by moat score — the top 95%.
The widest moat in the group is IDEXX Laboratories, Inc. (IDXX)
at 78/100.
Moat scores for companies ranked near AWH in Diagnostics & Research
How AWH scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Not measurable
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Not measurable
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Not measurable
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Not measurable
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Not measurable
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Not measurable
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Aspira Women's Health Inc. (AWH) scores 0 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #59 of 62 scored companies in Diagnostics & Research, the top 95%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research.
How does Aspira Women's Health Inc. compare with other Diagnostics & Research companies?
Aspira Women's Health Inc. ranks #59 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Applied DNA Sciences, Inc. (APDN) at 0 just above it and Check-Cap Ltd. (CHEK) at 0 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.
Why is Aspira Women's Health Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Aspira Women's Health Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and AWH scores: Pricing Power & Consumable Moat (not measurable), R&D Pipeline & Capital Returns (not measurable), FCF Quality & Cash Conversion (not measurable), Commercial Execution (not measurable), Capital Structure & Resilience (not measurable), Growth Durability (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.